Evidence is provided that proteolytic cleavage of collagen type IV results in the exposure of a functionally important cryptic site hidden within its triple helical structure. Exposure of this cryptic site was associated with angiogenic, but not quiescent, blood vessels and was required for angiogenesis in vivo. Exposure of the HUIV26 epitope was associated with a loss of α1β1 integrin binding and the gain of αvβ3 binding. A monoclonal antibody (HUIV26) directed to this site disrupts integrin-dependent endothelial cell interactions and potently inhibits angiogenesis and tumor growth. Together, these studies suggest a novel mechanism by which proteolysis contributes to angiogenesis by exposing hidden regulatory elements within matrix-immobilized collagen type IV.
Skip Nav Destination
Article navigation
3 September 2001
Article|
September 03 2001
Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo
Jingsong Xu,
Jingsong Xu
1Departments of Radiation Oncology and Cell Biology, Kaplan Cancer Center, New York University School of Medicine, New York, NY 10016
Search for other works by this author on:
Dorothy Rodriguez,
Dorothy Rodriguez
1Departments of Radiation Oncology and Cell Biology, Kaplan Cancer Center, New York University School of Medicine, New York, NY 10016
Search for other works by this author on:
Eric Petitclerc,
Eric Petitclerc
1Departments of Radiation Oncology and Cell Biology, Kaplan Cancer Center, New York University School of Medicine, New York, NY 10016
Search for other works by this author on:
Jenny J. Kim,
Jenny J. Kim
1Departments of Radiation Oncology and Cell Biology, Kaplan Cancer Center, New York University School of Medicine, New York, NY 10016
Search for other works by this author on:
Masanori Hangai,
Masanori Hangai
2Department of Ophthamology, Doheny Eye Institute, University of Southern California, Los Angeles, CA 90033
Search for other works by this author on:
S. Moon Yuen,
S. Moon Yuen
2Department of Ophthamology, Doheny Eye Institute, University of Southern California, Los Angeles, CA 90033
Search for other works by this author on:
George E. Davis,
George E. Davis
3Department of Pathology and Laboratory Medicine, Texas A & M University Health Science Center, College Station, TX 77843
Search for other works by this author on:
Peter C. Brooks
Peter C. Brooks
1Departments of Radiation Oncology and Cell Biology, Kaplan Cancer Center, New York University School of Medicine, New York, NY 10016
Search for other works by this author on:
Jingsong Xu
1Departments of Radiation Oncology and Cell Biology, Kaplan Cancer Center, New York University School of Medicine, New York, NY 10016
Dorothy Rodriguez
1Departments of Radiation Oncology and Cell Biology, Kaplan Cancer Center, New York University School of Medicine, New York, NY 10016
Eric Petitclerc
1Departments of Radiation Oncology and Cell Biology, Kaplan Cancer Center, New York University School of Medicine, New York, NY 10016
Jenny J. Kim
1Departments of Radiation Oncology and Cell Biology, Kaplan Cancer Center, New York University School of Medicine, New York, NY 10016
Masanori Hangai
2Department of Ophthamology, Doheny Eye Institute, University of Southern California, Los Angeles, CA 90033
S. Moon Yuen
2Department of Ophthamology, Doheny Eye Institute, University of Southern California, Los Angeles, CA 90033
George E. Davis
3Department of Pathology and Laboratory Medicine, Texas A & M University Health Science Center, College Station, TX 77843
Peter C. Brooks
1Departments of Radiation Oncology and Cell Biology, Kaplan Cancer Center, New York University School of Medicine, New York, NY 10016
Address correspondence to Peter C. Brooks, Departments of Radiation Oncology and Cell Biology, Kaplan Cancer Center, Rusk Building Room 806, New York University School of Medicine, 400 East 34th St., New York, NY 10016. Tel.: (212) 263-3021. Fax: (212) 263-3018. E-mail: [email protected]
*
Abbreviations used in this paper: CAM, chorioallantoic membrane; ECM, extracellular matrix; HUVEC, human umbilical vein endothelial cell; MMP, matrix metalloproteinase; SCID, severe combined immunodeficient.
Received:
March 26 2001
Revision Received:
July 06 2001
Accepted:
July 13 2001
Online ISSN: 1540-8140
Print ISSN: 0021-9525
The Rockefeller University Press
2001
J Cell Biol (2001) 154 (5): 1069–1080.
Article history
Received:
March 26 2001
Revision Received:
July 06 2001
Accepted:
July 13 2001
Connected Content
This article has been corrected
Correction: Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo
Citation
Jingsong Xu, Dorothy Rodriguez, Eric Petitclerc, Jenny J. Kim, Masanori Hangai, S. Moon Yuen, George E. Davis, Peter C. Brooks; Proteolytic exposure of a cryptic site within collagen type IV is required for angiogenesis and tumor growth in vivo . J Cell Biol 3 September 2001; 154 (5): 1069–1080. doi: https://doi.org/10.1083/jcb.200103111
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionEmail alerts
Advertisement
Advertisement